The fermentation processes that are used by biopharmaceutical manufacturers have shown to lead to increasing quantities of therapeutic proteins. However, this increase in turn leads to capacity bottlenecks in the subsequent purification process known as downstream processing and is associated with high costs. Downstream processing comprises up to 80 per cent of the entire production costs. Producers are increasingly recognising the present need for improvement and have shifted their focus from improving the production process upstream to improving the downstream process. Thanks to the progress attained in molecular biology, which has led to better cell culture methods, pharmaceutical producers can now increase the yield of monoclonal antibodies the fastest growing marketing segment from the milligram scale to the gram scale. Experts state that a tenfold from 0.
|Country:||Turks & Caicos Islands|
|Published (Last):||7 July 2019|
|PDF File Size:||15.95 Mb|
|ePub File Size:||8.29 Mb|
|Price:||Free* [*Free Regsitration Required]|
The fermentation processes that are used by biopharmaceutical manufacturers have shown to lead to increasing quantities of therapeutic proteins. However, this increase in turn leads to capacity bottlenecks in the subsequent purification process known as downstream processing and is associated with high costs. Downstream processing comprises up to 80 per cent of the entire production costs.
Producers are increasingly recognising the present need for improvement and have shifted their focus from improving the production process upstream to improving the downstream process. Thanks to the progress attained in molecular biology, which has led to better cell culture methods, pharmaceutical producers can now increase the yield of monoclonal antibodies the fastest growing marketing segment from the milligram scale to the gram scale.
Experts state that a tenfold from 0. This shows that the upstream costs are inversely proportional to the titre, but the same is not true for the downstream processing costs. In order to satisfy larger market demands, the protein load on the chromatography steps needs to be increased. This can either be achieved by increasing the number of cycles or by investing in larger chromatography columns up to a diameter of two metres.
This, however, also leads to larger volume loads on the subsequent filtration steps, leading to longer filtration times or the need for larger areas. However, real problems are expected to show up with the isolation of proteins, since an increase in protein yields will require manufacturers to invest in larger equipment and more materials in order to handle the larger quantities of protein produced. Although large chromatographic columns are technically feasible, they require larger utilities and floor space to match the larger size of the columns, which is something that is not always possible for the existing facilities.
It is, therefore, quite understandable that the biopharmaceutical industry is actively seeking less expensive alternatives, and not only in view of the growing cost pressure in the healthcare sector. One idea to overcome the problem at hand is to replace chromatography resins, for example Protein A which can bind mammalian proteins , which is very costly, or to reduce the number of column chromatography steps from three to two, and eventually to one.
Membrane absorbers might also be a potential alternative for counteracting the downstream bottleneck. For Germany, which is the second-largest biopharmaceuticals producer worldwide, new purification methods are needed in order to remain competitive.
The purification problem faced by the biopharmaceutical producers can be better understood by looking at the historical development of red biotechnology. In their incubation phase , biotech start-ups were primarily focused on developing recombinant proteins to be used for substitution therapy and obtaining marketing authorisation for their products. In many cases, the laboratory processes were directly implemented into the production scale.
In bioreactors, E. This method led to 10 to mg of protein per litre. At that time, the biopharmaceutical industry was mostly interested in improving production and put purification processes on the backburner.
The throughput had to be increased to the mg scale. As a result, manufacturers had to think of new ways to change their manufacturing processes in order to match the purification capacity with upstream productivity. The manufacturing portfolio shifted from prokaryotic to eukaryotic systems due to the growing importance of glycoproteins. The growing understanding of molecular and cellular processes led to an increase in the expression rates of existing cell lines and to the development of new expression systems, such as NSO mouse myeloma cells.
Standardised fermentation methods led to protein yields of up to 2 g per litre that were produced with animal cell culture systems, and up to twice as much in the development process. Productivity increased by to fold. Innovation in the downstream processing area was much more inactive. As upstream productivity increased, the binding capacity of chromatographic materials that are used for the subsequent purification of proteins, increased by no more than a factor of three.
Since the first-generation production facilities focused mainly on upstream processing, the existing facilities usually did not have the equipment or floor space to meet the increase in fermentation titres. Expansions became necessary, which in turn led to costs reaching to the two-figure million range.
Two types of large-scale production facilities were primarily used at the end of the s. Both types were used as multi-product facilities employing the fed-batch technology. The reactors had a capacity of 6 x 15, litres with turn-over periods of three weeks and a total annual capacity of to kg protein.
Although the productivity increased drastically thanks to improved cell culture methods and fermentation conditions, the technical fermentation process remained, in principle, unchanged.
The up- and downstream processes drifted more and more apart. Product- and process-immanent impediments Several steps are required to purify the therapeutic proteins produced in bioreactors. These contaminations are the result of the processes, or the products themselves, and can pose a danger to those patients treated with impure substances.
Therefore, care must be taken to reduce the amount of undesired substances down to a harmless amount. The contaminations, moreover, might also have detrimental effects on the product itself denaturation. The process-related contaminations include the remains of the host cells proteins, nucleic acids or of the cell culture components of the culture media used or can be the result of the processing salts or detached chromatographic ligands.
The contaminations might also be related to the product itself, i. Polymers and protein aggregates are also undesired product-specific variants. It is also necessary to remove all the other substances of microbiological, biochemical or chemical origin, which are directly part of the production process, for example viruses that might occur in cell cultures.
It is certainly possible to improve biopharmaceutical purification. However, the large-scale production of proteins is associated with exorbitant costs. The time required to establish a new purification process also plays a major role in process economics.
In addition, the development of the process must be coordinated with the preclinical and clinical development of the drug. And last but not least, there is no "one and only" purification process. Every substance requires a specific purification process, which is adjusted to the substance's specific biochemical and biophysical profile and its specific fermentation conditions. Downstream processing operations, i. The first step involves the isolation, concentration and stabilisation of the target protein capturing , followed by the removal of viruses.
The third step involves the removal of contaminations, such as nucleic acids, unwanted proteins and endotoxins intermediate purification. The final processing step involves the removal of trace contaminants that might compromise the safety of the product polishing. The typical operations are filtration and precipitation, as well as column chromatrophic methods, wherein a broad range of methods and materials are available. The purification of the target protein or molecule depends on its form, size, solubility, surface charge or its biospecific affinity to binding partners.
This also increases the number of processes that can be used to purify the proteins. Considering the enormous cost and time pressure, as well as the production-plant-specific constraints, manufacturers are having a tough time developing optimal purification steps for the target molecule or protein. Usually, these processes are developed according to the trial and error principle and are established as soon as the process "functions".
It is difficult to omit steps in the purification process and not compromise thereby the safety of the protein such as the removal of viruses or DNA. However, representatives of the pharmaceutical industry believe that it is possible to optimise the procedure and potentially also combine individual or partial steps of the process. Column chromatography is usually regarded as the major cost driver. Besides for the fixed costs, the column membranes that are used for the purification of the proteins swallow a large proportion of the costs.
Those looking for reasons as to why downstream processing has been neglected for such a long time are well advised to take the following into account: while the establishment of master cell banks and the optimisation of the cell culture techniques were achieved without the help of others, the purification of proteins, however, has always involved third parties. This has made innovation quite difficult.
From a manufacturer's perspective, downstream processes can be effectively improved by using less complex culture media so-called minimal media, which only contain the minimum nutrients required.
High priority is also given to efforts trying to reduce the purification steps. This would save a lot of time and money and simultaneously reduce the substance losses occurring with any further purification step. Innovative gels and double binding capacity is also expected to increase the effectiveness of the chromatographic processes.
Some of the authors discussing the problems experienced in upstream and downstream processing seem to deny the fact that the biopharmaceutical industry is experiencing a downstream bottleneck, claiming in turn that the most severe bottlenecks occur in facilities that are 10 to 20 years old, which is where those operators were unable to anticipate the increase in upstream productivity. Other people believe that the purification issues are over-hyped since only very few products are manufactured at a very large scale.
What seems to speak against the downstream bottleneck idea, is the notion that modern biopharmaceuticals are becoming more potent, which reduces dosing and in many cases also the batch sizes.
One thing seems clear: the biopharmaceutical sector is undergoing a paradigm change. Some people are increasingly making suggestions to reverse the current way of thinking. This is also the case with many other mature technologies. Why not split the batches or purify the proteins in two partial steps in order to not run into capacity limitations? Why is it always necessary to purify all the fermented proteins? Is it really necessary to spend a two-figure million sum on reorganising a downstream process that only leads to a productivity increase of 10 to 20 per cent?
Downstream processing: bottleneck purification process The fermentation processes that are used by biopharmaceutical manufacturers have shown to lead to increasing quantities of therapeutic proteins. Biochemical purification in biopharmaceutical production. The photo shows chromatography columns, and buffer collection containers in the background.
As a business owner or operations manager responsible for production, understanding the supply chain is essential to the success of your business. Any obstacle or impediment to the smooth flow of production can mean thousands of dollars lost and problems with the clients who depend on the delivery of your goods. The manufacturing production process can be pictured like a river. It's not unusual to hear people involved in production make frequent reference to "upstream" and "downstream" parts of the process. Upstream refers to the material inputs needed for production, while downstream is the opposite end, where products get produced and distributed.
Downstream processing: bottleneck purification process
Downstream processing refers to the recovery and the purification of biosynthetic products, particularly pharmaceuticals, from natural sources such as animal or plant tissue or fermentation broth, including the recycling of salvageable components and the proper treatment and disposal of waste. It is an essential step in the manufacture of pharmaceuticals such as antibiotics, hormones e. Downstream processing is usually considered a specialized field in biochemical engineering , itself a specialization within chemical engineering , though many of the key technologies were developed by chemists and biologists for laboratory-scale separation of biological products. Downstream processing and analytical bioseparation both refer to the separation or purification of biological products, but at different scales of operation and for different purposes. Downstream processing implies manufacture of a purified product fit for a specific use, generally in marketable quantities, while analytical bioseparation refers to purification for the sole purpose of measuring a component or components of a mixture, and may deal with sample sizes as small as a single cell.
The Definitions of "Upstream" and "Downstream" in the Production Process